fig4
![Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium](https://image.oaes.cc/86f2c794-f7a4-470b-a892-451b19dcdbe8/vp8095.fig.4.jpg)
Figure 4. Immunoblot results in chronically ischemic myocardium with canagliflozin and sitagliptin. Data shown from immunoblot experiments in chronically ischemic myocardium in swine treated with canagliflozin (CANA, n = 8), sitagliptin (SIT, n = 5), and vehicle with no drug (CON, n = 8). *signifies a P value of less than 0.05.